040-24051777
www.likhithadiagnostics.com
info@likhithadiagnostics.com

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:20
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830300

Clinical Biochemistry

GLYCATED HAEMOGLOBIN (HBA1C)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
GLYCATED HAEMOGLOBIN (HBA1C) Method:HPLC	5.36	%	Normal : < 5.7 Diabetes Mellitus : > 6.5 Increased Risk of Diabetes/Pre - Diabetes : 5.7 - 6.4
AVERAGE BLOOD GLUCOSE Method:Calculation	107.13	mg/dL	90 - 120 - Excellent control121 - 150 - Good Control151 - 180 - Average Control181 - 210 - Action Suggested> 211 - Panic Value

Sample Type : WB EDTA

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:18
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830000

Clinical Pathology

COMPLETE URINE EXAMINATION (CUE)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
PHYSICAL EXAMINATION			
COLOUR	PALE YELLOW	-	Straw to Yellow
APPEARENCE	CLEAR	-	Clear
CHEMICAL EXAMINATION			
REACTION	6.0	-	4.6 - 8.0
Method:pH (Double) Indicator			
SPECIFIC GRAVITY	1.015	-	1.003 - 1.035
Method:pH Indicator			
PROTEINS	NEGATIVE	-	Negative
Method:Protein error of Indicator			
GLUCOSE	NEGATIVE	-	Negative
Method:GOD POD			
BILIRUBIN (BILE PIGMENTS)	NEGATIVE	-	Negative
Method:Diazonium Method/Fouchets Method			
BILE SALTS	ABSENT	-	Absent
Method:Hays Method			
KETONE BODIES	NEGATIVE	-	Negative
Method:Nitroprusside Reaction/Rotheras Method			
UROBILINOGEN	ABSENT	-	Normal
Method:Diazonium Method			
NITRITE	NEGATIVE	-	Negative
Method:Diazonium Method			
MICROSCOPIC EXAMINATION			
Pus Cells	1-2 /HPF	cells/hpf	0-4
RBC.	NIL	cells/hpf	0-2
Epithelial Cells	OCCASIONAL	cells/hpf	0-4
CASTS	ABSENT	-	Absent
CRYSTALS	ABSENT	-	Absent
Others	NIL	-	
Blood	ABSENT	-	Absent
Method:Physical Examination			

Sample Type : URINE

Please Correlate With Clinical Findings If Necessary Discuss

* This Is an Electronically Authenticated Report *

040-24051777
www.likhithadiagnostics.com
info@likhithadiagnostics.com

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	:
Age\Sex	: 31 Years\Male	**Received**	:
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	:
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	:

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

040-24051777
www.likhithadiagnostics.com
info@likhithadiagnostics.com

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:20
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830200

Clinical Biochemistry

FASTING BLOOD GLUCOSE (FBS)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
FASTING PLASMA GLUCOSE-	**113.89**	mg/dL	74-99

Method:Hexokinase/GOD-POD

Sample Type : Flouride plasma(F)

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 18-Sep-2022 /10:53
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 18-Sep-2022 /12:11
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830100

Clinical Biochemistry

GAMMA GLUTAMYL TRANSFERASE (GGT)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
GAMMA GLUTAMYL TRANSFERASE	21.00	U/L	8-61

Method:Enzymatic

Sample Type : Serum

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

pavani

Dr.T.PAVANI KIRANMAI
MD BIOCHEMISTRY

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:20
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830300

Haematology

COMPLETE BLOOD PICTURE(CBP)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
HAEMOGLOBIN Method:Spectrophotometry	16.3	g/dL	13.0-17.0
P C V Method:Automated cell counter.	**51.3**	%	40-50
M C V Method:calculated	86.7	fl	83-101
M C H Method:calculated	27.5	pg	27-32
M C H C Method:calculated	31.8	g/dL	31.5-34.5
R D W Method:calculated	13.5	%	11.6-14.0
R D W (SD) Method:calculated	44.9	fl	39-46
TOTAL RBC COUNT Method:Electrical Impendance	**5.91**	mil./cmm	4.5-5.5
PLATELET COUNT Method:Electrical Impendance	1.67	lakhs/cumm	1.5-4.1
TOTAL WBC COUNT Method:Electrical Impendance	6,100	cells/cmm	4000-10000
DIFFERENTIAL COUNT.			
NEUTROPHILS. Method:Flow Cytometry / Microscopy.	46	%	40-80
LYMPHOCYTES Method:Flow Cytometry / Microscopy.	**43**	%	20-40
EOSINOPHILS Method:Flow Cytometry / Microscopy.	04	%	1-6
MONOCYTES Method:Flow Cytometry / Microscopy.	07	%	2-10
BASOPHILS Method:Flow Cytometry / Microscopy.	00	%	0-2

PERIPHERAL SMEAR.

Sample Type : WB EDTA

Please Correlate With Clinical Findings If Necessary Discuss

* This Is an Electronically Authenticated Report *

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	:
Age\Sex	: 31 Years\Male	**Received**	:
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	:
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	:

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:54
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830300

Haematology

ERYTHROCYTE SEDIMENTATION RATE (ESR)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
*I HOUR	20	mm/hr	Upto 15

Method:Modified Westergren

Sample Type : WB EDTA

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.B.MALLIKARJUN
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:20
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830100

Clinical Biochemistry

KIDNEY FUNCTION TEST (UREA, CREA, Na+, K+)(KFT)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
BLOOD UREA. Method:Urease (GLDH) /Kinetic	11.63	mg/dL	16-48
SERUM CREATININE Method:Jaffes Kinetic	**1.54**	mg/dL	0.90-1.3
SERUM SODIUM Method:ISE Direct	138.1	mmoL/L	135-150
SERUM POTASSIUM Method:ISE Direct	4.0	mmoL/L	3.5-5.0
SERUM CHLORIDE Method:ISE Direct	105.5	mmoL/L	94-110

Sample Type : Serum

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:20
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830100

Clinical Biochemistry

LIPID PROFILE (LPD)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
TOTAL CHOLESTEROL Method:Spectrophotometry	136.63	mg/dL	Desirable : <200 Borderline : 200 - 239 High : >240
H D L CHOLESTEROL Method:Enzymatic-CHOD-POD	35.06	mg/dL	Negative Risk >60 High Risk : < 40
L D L CHOLESTEROL Method:Friedewald Formula	68.87	mg/dL	<150
V L D L CHOLESTEROL Method:Friedewald Formula	32.7	mg/dL	6.0-38.0
TRIGLYCERIDES, Method:Enzymatic	**163.52**	mg /dl	Normal: <150 Borderline: 150 -199 High: 200 - 499 Very High: >/= 500
CHOL/HDL RATIO	3.9	-	3.5-5.0
LDL/ HDL Ratio	1.96	-	

Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

Reference: National Cholesterol Education Program Adult Treatment Plan III (NCEP-ATP 111) report.

Sample Type : Serum

Please Correlate With Clinical Findings If Necessary Discuss

* This Is an Electronically Authenticated Report *

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:20
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830100

Clinical Biochemistry

LIVER FUNCTION TEST (LFT)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
TOTAL BILIRUBIN	**1.23**	mg/dL	0.3-1.2
Method:Diazo Method			
DIRECT BILIRUBIN	**0.23**	mg /dl	0-0.2
Method:Diazo Method			
INDIRECT BILIRUBIN	**1.00**	mg /dl	0.2-0.8
Method:Diazo Method			
ALKALINE PHOSPHATASE	89.71	U/L	40-129
Method:PNPP-AMP Buffer/Kinetic			
SGOT / AST	23.08	U/L	0-41
Method:Spectrophotometry			
SGPT / ALT	24.74	U/L	Upto 40
Method:MOD-IFCC			
TOTAL PROTEIN.	6.76	gm/dL	6.6-8.7
Method:Biuret/End Point			
ALBUMIN	4.5	gm/dL	3.5-5.2
Method:BCG, Nephelometry, Immunoturbidimetry			
GLOBULIN	**2.3**	gm/dL	2.5-3.5
A/G RATIO	2.0	Calculated	1-2.1
Method:Biruet/End Point			

Sample Type : Serum

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:20
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830100

Serology

HIV (I & II) (TRIDOT)

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
HIV - I Antibody Method:Immunoconcentration	NEGATIVE	-	
HIV - II Antibody Method:Immunoconcentration	NEGATIVE	-	

Comments :
1.This is a screening test only.
2. Non Reactive result implies that antibodies to HIV 1/2 have not been detected in the sample. This means the patient has either not been exposed to HIV 1/2 infection or the sample has been tested during the "window phase" i.e. before the development of detectable levels of antibodies. Hence a Non Reactive result does not exclude the possibility of exposure or infection with HIV 1/2.
3.All positive specimen should be further confirmed by WESTERN BLOT OR HIV PCR.

Recommendations:
1.Results to be clinically correlated.
2.Rarely false negativity/positivity may occur.

Sample Type : Serum

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 18-Sep-2022 /10:51
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 18-Sep-2022 /12:10
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830000

Special Biochemistry

URINE FOR COTININE

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
COTININE	NEGATIVE	-	NEGATIVE

Method:Rapid Visual Immunoassay

Sample Type : Urine- 5ml

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.A.V.NAIDU
MD PATH
Consult Pathologist

****** END OF REPORT ******

TEST REPORT

Reg.No	: TPT0061020	**Reg.Date**	: 17-Sep-2022 /15:59
Name	: MR.YASWANTH MYLAMURI	**Collection**	: 17-Sep-2022 /15:27
Age\Sex	: 31 Years\Male	**Received**	: 17-Sep-2022 /16:10
Referred By	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Report**	: 17-Sep-2022 /17:20
Referral Dr	: GOWELNEXT SOLUTIONS PRIVATE LIMITED	**Barcode**	: 000974830100

Serology

HBSAG

TEST NAME	OBSERVED VALUE	UNITS	BIOLOGICAL REF. RANGE
Hbs Ag(Rapid)	NEGATIVE	-	

Method:Immunochromatography

Notes : 1.Discrepant results may be observed during pregnancy, patients receiving mouse monoclonal antibodies for diagnosis or therapy & mutant forms of HBsAg
2.For diagnostic purposes, results should be used in conjunction with clinical history and other hepatitis markers for Acute or Chronic infection
3. For monitoring HBsAg levels, Quantitative HBsAg molecular assay is recommended

Comments:
1.Hepatitis B Virus (HBV) is a member of the Hepadna virus family causing infections of the liver with extremely variable clinical features.
2. Hepatitis B is transmitted primarily by body fluids especially serum and also spread effectively sexually and from mother to baby.
3. In most individuals HBV hepatitis is self limiting, but 1-2% normal adolescents and adults develop Chronic Hepatitis.
4.Frequency of chronic HBV infection is 5-10% in immunocompromised patients and 80% in neonates. The initial serological marker of acute infection is HBsAg which typically appears 2-3 months after infection and disappears 12-20 weeks after onset of symptoms.
5.Persistence of HBsAg for more than six months indicates development of carrier state or Chronic liver disease.
Uses: 1.To diagnose suspected HBV infection and monitor the status of infected individuals

2. To evaluate the efficacy of antiviral drugs

3. Routine screening of blood and blood products to prevent transmission of Hepatitis B virus (HBV) to recipients For Prenatal Screening of pregnant women.

Sample Type : Serum

Please Correlate With Clinical Findings If Necessary Discuss
* This Is an Electronically Authenticated Report *

Dr.MALLIKARJUN B
MD. PATH
Consultant Pathologist

****** END OF REPORT ******